Navigation Links
Data Published at ASCO Find Correlation Between ChemoFx(R) Assay and Significantly Improved Overall Survival in Patients With Ovarian Cancer
Date:5/20/2008

Analysis Reveals Overall Survival Could be Extended if Patients Receive the

Most Effective Treatment Identified by ChemoFx

CHICAGO, May 20 /PRNewswire/ -- Precision Therapeutics Inc. announced today that the ChemoFx(R) Assay, a cell-based test that examines the response of a specific patient's tumor to various chemotherapies, correlates with significantly longer overall survival (OS) in patients with primary ovarian cancer. Patients who received a treatment determined by ChemoFx to lead to the best tumor response had an overall survival 1.4 times longer than those receiving a treatment shown by ChemoFx to be non-responsive.

Despite the fact that all patients had the same type of tumor, 88 percent of patients exhibited varying degrees of response to different agents when evaluated by the cell-based test. The analysis also found that nearly two-thirds of patients' tumors were more responsive to a treatment identified by ChemoFx, than to the treatment they actually received. Based on these results, a mathematical model was created to estimate survival had patients been treated with a drug that ChemoFx identified as more likely to result in a greater tumor response. The analysis found that median OS could be extended as much as 23 to 38 months.

"These overall survival data demonstrate that the responsiveness to treatment established by this sensitivity assay in the laboratory setting, may in fact translate into meaningful clinical outcomes for patients," said Thomas J. Herzog, MD, director of gynecologic oncology at the Columbia University Medical Center and lead investigator of the study. "If these results are confirmed in current ongoing trials, this will be a significant step towards establishing individualized treatment strategies for patients who will require chemotherapy."

About the Study

Patients analyzed in the study had stage II-IV primary epithelial ovarian cancer that was tested by ChemoFx between 1997 an
'/>"/>

SOURCE Precision Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... March 27, 2015 XRpro Sciences, Inc., ... discovery and development services which features high throughput ... industry, announced financial results for the year ended ...  Tyson, Chairman of XRpro Sciences commented, "We have ... from development stage to commercial stage in large ...
(Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2
... Life Sciences Holdings, Inc. (OTC Bulletin ... in the discovery, development and commercialization of novel drugs ... diseases, announced today that Dawson James Securities Inc., has ... report highlights Restanza™ (cethromycin) as a promising late-stage antibacterial ...
... 2010 HealthLeaders-InterStudy, a leading provider of managed ... a shift toward coordinated patient care in Portland, ... to the Portland, Maine Market Overview, ... coordinated care models such as patient-centered medical homes ...
Cached Medicine Technology:Dawson James Initiates Research Coverage of Advanced Life Sciences 2Dawson James Initiates Research Coverage of Advanced Life Sciences 3Consolidated Portland, Maine Healthcare Market Will Hamper Pharmaceutical Reps' Access to Physicians 2
(Date:3/28/2015)... March 28, 2015 ARDX will sponsor the ... 12pm -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... an empowering event for women in the Hampton Roads region. ... Stories of Women’s Lives. Women grow stronger through sharing ... other. This year the WWC™ theme is T-talk where ...
(Date:3/28/2015)... Paso Robles, CA (PRWEB) March 28, 2015 ... damage restoration specialists , this week released a report ... worsen the symptoms of asthma sufferers, and according to ... healthy children. , According to the Environmental Protection ... can develop asthmatic reactions. Breathing in mold may trigger ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 The ... from dating experts Samantha Sanderson and Jason Rogers has ... buzz of media attention. The commotion surrounding the course's ... prompting him to publish an in-depth review of the ... when the men in their lives suddenly start pulling ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 In her mid-forties ... prevented her from working, Monica K. arrived at JET ... mending department quiet, defensive and scared. The owners and staff ... Support Services (EPSS) to offer jobs to challenged residents ... patience and a willingness to begin with the end in ...
(Date:3/27/2015)... The federal court overseeing thousands of ... medication increases the risk that a patient will develop ... Dismiss four individual cases that had been filed in ... in the U.S. District Court, District of South Carolina, ... were warranted because the plaintiffs in those claims had ...
Breaking Medicine News(10 mins):Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3
... of Matthew L. Myers, President, Campaign for ... following is a,statement of Matthew L. Myers, President, ... for Latin America and the world, both the,Mexico ... Tuesday,took significant action to reduce tobacco use and ...
... 2008) MIT graduate student and synthetic biologist ... pose threats to human health. His current mission: ... M.D. candidate and Ph.D. in the Harvard-MIT Division ... $30,000 Lemelson-MIT Student Prize for inventing processes that ...
... Bradley Kropp of Faculty of 1000 Medicine, researchers find ... of bowel function after gastrointestinal surgery a problem ... , Authors of the paper published in Urology evaluated ... them 5 pieces of chewing gum per day after ...
... TRAVERSE CITY, Mich., Feb. 27 Versus,Technology, Inc. ... its first fiscal quarter ended January 31, 2008, ... same quarter of the prior,year. Versus, quarterly revenues ... of major customer projects. Accordingly, the revenues,reported in ...
... by Swiss-Based In-House Counsel, To Proceed against Altria Group, Inc. and ... ... Inc., NEW YORK, Feb. 27 Broach & Stulberg, LLP announced,today ... for the Southern District of New York has denied motions to,dismiss age ...
... Feb. 27 To coincide with the annual,HIMSS ... announced a new release and new pricing of,its ... users,of EMR (Electronic Medical Records) software to scan ... package which is hosted on,Citrix(R) or Windows Terminal ...
Cached Medicine News:Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 2Health News:Mexico City's New Smoke-Free Law Sets Example for Latin America and World 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 2Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 3Health News:Bacteria beware: MIT student invents knock-out punch for antibiotic resistance 4Health News:Versus Technology Announces First Quarter Results 2Health News:Versus Technology Announces First Quarter Results 3Health News:Versus Technology Announces First Quarter Results 4Health News:Versus Technology Announces First Quarter Results 5Health News:Versus Technology Announces First Quarter Results 6Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 2Health News:Court Denies Tobacco Giants' Motions to Dismiss Claims Alleging Explicit Age Discrimination and Retaliation 3Health News:RemoteScan - Scanner Connectivity Software for EMR (Electronic Medical Record) Systems 2
... has created this extremely versatile and efficient ... liquid handling. With EDOS, high sample throughput ... with ease. ,The smallest volume that ... corresponding Combitip. The easy-to-follow user menus presented ...
... Dilutor-Dispenser is designed to transfer ... the clinical, biological, and chemical ... and performance as Gilsons other ... is ideal for routine laboratory ...
... synQUAD technology is a patented non-contact dispensing ... with a microsolenoid valve and stage stepper ... of liquid onto various slides, plates, or ... well, coefficient of variation (CVs) are less ...
16 channel Parallel dispenser using Positive Air Displacement Technology...
Medicine Products: